Hang Hock Shim

Hang Hock Shim

Auto-generated profile, based on publicly available information

Hang Hock Shim

Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2018 in JGH Open
Verified
Journal Article
Open access
PDF file
HSHang Hock Shim
Hang Hock Shim
PCPak Wo Chan
Pak Wo Chan
SCSai Wei Chuah
Sai Wei Chuah
BSBrian J Schwender
Brian J Schwender
SKSan Choon Kong
San Choon Kong
KLKhoon Lin Ling
Khoon Lin Ling
Recent advancement in the understanding of the pathophysiology of inflammatory bowel disease has seen an expansion in therapeutic options. Vedolizumab, a selective α4β7 inhibitor, and ustekinumab, an IL 12/23 p40 inhibitor, have provided the much‐awaited out‐of‐class alternatives for patients who have failed or who are intolerant to anti‐Tumor Necrosis Factor (TNF) therapy. However, questions remain as to how we may best use these novel therapeutic agents. We evaluate the evidence available from randomized controlled trials and postmarketing cohort studies and discuss their safety, efficacy, and limitations, in relation to anti‐TNF therapy, in optimizing the treatment outcomes.

9 October 2018 in Journal of the Canadian Association of Gastroenterology
Verified
Journal Article
Open access
PDF file
YLYvette Leung
Yvette Leung
HSHang Hock Shim
Hang Hock Shim
Rune WilkensRune Wilkens
Rune Wilkens
DTDivine Tanyingoh
Divine Tanyingoh
EAElnaz Ehteshami Afshar
Elnaz Ehteshami Afshar
CSCynthia H Seow
Cynthia H Seow
Background and Aims: Maintaining disease remission improves outcomes for pregnant women with Crohn’s disease (CD). As symptoms may correlate poorly with disease activity in the gravid state, we investigated the utility of bowel sonography during pregnancy to assess disease activity. Methods: We conducted a prospective observational cohort study of pregnant women with CD undergoing bowel sonography between July 1, 2012, and December 1, 2016. Clinically active disease was defined using standardized clinical indices (Harvey Bradshaw Index >4 for active disease). Sonographic findings were graded as inactive (normal, mild) or active (moderate, severe) by expert radiologists. Results: There were 91 pregnancies in 82 CD patients. Symptoms were present in 12 pregnancies; however, eight (67%) had sonographic findings of inactive disease, and escalation of therapy was not initiated. Conversely, sonographically active disease in seven asymptomatic pregnancies resulted in four women escalating therapy. The remaining three women declined escalation of therapy, one had a miscarriage, and the other two women had persistently active disease on sonography and endoscopy at one-year postpartum. Conclusions: Bowel ultrasound may detect subclinical inflammation in asymptomatic pregnant women with CD and stratify CD activity in symptomatic patients. Therefore, bowel sonography should be considered as a useful adjunct for the assessment of the pregnant woman with Crohn’s disease.

31 August 2018 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
PDF file
HSHang Hock Shim
Hang Hock Shim
SCSophie Carrie Shan Cai
Sophie Carrie Shan Cai
WCWebber Chan
Webber Chan
JLJenny Guek Hong Low
Jenny Guek Hong Low
HTHiok Hee Tan
Hiok Hee Tan
KLKhoon Lin Ling
Khoon Lin Ling
The introduction of ustekinumab, an interleukin [IL]12/23 p40 inhibitor, to the therapeutic armamentarium of Crohn’s disease has provided a much needed treatment option for patients who have failed conventional biologics with anti-tumour necrosis factor [TNF] and anti-integrin agents. Despite targeting two major cytokine pathways, the side effect profile of ustekinumab appears to be favourable in clinical trials. In particular, the risk of tuberculosis infection was observed to be lower than in patients who have received anti-TNF agents. The risk of non-tuberculosis mycobacterium infection, however, remains unknown. Here, we report the first case of a patient with Crohn’s disease who developed Mycobacterium abscessus infection while on ustekinumab treatment.

2 September 2019 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
HSHang Hock Shim
Hang Hock Shim
CMChristopher Ma
Christopher Ma
PKPaulo Kotze
Paulo Kotze
RPRemo Panaccione
Remo Panaccione
Crohn’s disease (CD) is a chronic inflammatory condition of the intestinal tract that is characterised by a relapsing and remitting course. Despite advancements in therapeutic options for CD, a substantial number of patients still require surgery for medically refractory disease or disease-related complications. Given the widespread adoption of biologic therapies for management of patients with moderate-to-severe CD, a high number of patients are likely to be on biologic therapy at time of needing intestinal surgery: the safety of biologics in perioperative setting is of great interest. While more clinical data are available for TNF antagonists and vedolizumab, the safety data for ustekinumab, an IL 12/23 inhibitor, is lacking. Here, we review the available data from published literature on the postoperative outcomes for CD patients exposed to ustekinumab perioperatively.

16 June 2022 in Gastroenterology
Verified
Journal Article
Closed access
BSBenedix Sim
Benedix Sim
MCMark Cheah
Mark Cheah
PCPak Wo Chan
Pak Wo Chan
MTMalcolm Tan
Malcolm Tan
HSHang Hock Shim
Hang Hock Shim
ESEnnaliza Salazar
Ennaliza Salazar